Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Withdrawn 2Unknown 2Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 7Prostatic Neoplasms, Castration-Resistant 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Cancer 1Breast Neoplasms 1

Interventions

enzalutamide 2apalutamide 2Abiraterone Acetate 2radium Ra 223 dichloride 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms, Castration-Resistant × Abiraterone Acetate × Clear all
NCT03173859 2020-11-18

AERA

University of Athens

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡